Quarterly UpdatesJul 7, 2026, 08:32 AM
Microbot Medical Reports >100% Q2 Revenue & Customer Growth
AI Summary
Microbot Medical Inc. announced significant operational growth for the second quarter ended June 30, 2026, reporting over 100% growth in both revenue and new customers compared to the first quarter. This performance follows the successful commencement of the Full Market Release of its LIBERTY Endovascular Robotic System in April. The company is expanding its U.S. sales footprint, planning to enter international markets, and has secured a second manufacturing site to support rising demand.
Key Highlights
- Reported greater than 100% growth in revenue for Q2 2026 compared to Q1 2026.
- Achieved greater than 100% growth in new customers for Q2 2026 compared to Q1 2026.
- LIBERTY Endovascular Robotic System Full Market Release commenced on April 13, 2026.
- Expanded U.S. sales territories from 4 to 8 during Q2 2026.
- Plans to increase U.S. sales territories to 12 by the end of 2026.
- Received marketing clearance for the LIBERTY system from the Israeli Ministry of Health.
- Entered an agreement with Lovell Government Services Inc. to serve federal healthcare systems.
- Established an agreement for a second manufacturing site to meet demand.
Price Impact
More from MBOT